CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Oncoxin-Viusid® +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03541772
NCT03541772Phase 2Completed
CompareCT.gov

"Combined Oncoxin-Viusid® Treatment With Radiotherapy and Chemotherapy in Patients With Head and Neck Cancer. Phase II, Randomized and Double-blind Study"

Catalysis SL·interventional·Posted May 31, 2018·Updated Jun 6, 2018

In Brief

A Phase 2 clinical trial evaluating Oncoxin-Viusid® and Placebo for Head Cancer Neck. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Nutritional supplements containing antioxidants seem to decrease toxicity associated with Radiotherapy (RT) and Chemotherapy (CT) in patients with malignant head and neck tumors. Oncoxin-Viusid® (OV) is a nutritional supplement with antioxidant, immunomodulator and antitumor effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead Cancer Neck
CountriesCuba
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 31, 2018
Enrollment StartJan 20, 2015
Primary CompletionOct 16, 2017
Study CompletionOct 30, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.1 years ago

Interventions

Oncoxin-Viusid®dietary

Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments

Placebodietary

Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments